Opportunity Information: Apply for RFA DK 09 011
Apply for RFA DK 09 011
- The National Institutes of Health in the food and nutrition health sector is offering a public funding opportunity titled "Beta Cell Biology Consortium (U01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research.
- This funding opportunity was created on Aug 14, 2009 and posted on Aug 14, 2009.
- Applicants must submit their applications by Nov 23, 2009. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $12,000,000.00 to eligible and selected applicants.
- Eligible applicants include: For profit organizations other than small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal governments (Federally recognized) Native American tribal organizations (other than Federally recognized tribal governments) Public and State controlled institutions of higher education Private institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education State governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Non domestic (non U.S.) Entities (Foreign Organizations) Tribally Controlled Colleges and Universities (TCCUs) .
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Beta Cell Biology Consortium (BCBC) U01 funding opportunity (RFA-DK-09-011) is a National Institutes of Health program led by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) that aims to build a coordinated, multi-institution research consortium focused on advancing beta cell biology and translation-relevant strategies for diabetes. The core idea is to fund several teams under a cooperative agreement structure so they can work in a deliberately collaborative way, share data and materials, and collectively produce research resources that would be difficult for any single lab to generate alone. The consortium is associated with the BCBC website (www.betacell.org), signaling an organized network with shared goals and infrastructure.
Scientifically, the announcement targets four major research directions that all connect to restoring or preserving functional insulin-producing beta cells. First, it supports projects that use knowledge and signals from pancreatic development to guide the direct differentiation of pancreatic beta cells and islets from stem cells or progenitor cells, with the long-term goal of enabling cell replacement therapies for diabetes. Second, it invites research on stimulating beta cell regeneration in the adult pancreas, emphasizing approaches that could increase beta cell mass in people with diabetes by reawakening or enhancing regenerative capacity. Third, it focuses on cellular reprogramming strategies, meaning work that converts progenitor or adult cell types into pancreatic beta cells either in vitro (in the lab) or in vivo (within living organisms), again framed as a route toward cell replacement therapies. Fourth, it encourages studies that examine the progression of human type 1 diabetes using patient-derived cells and tissues transplanted into humanized mouse models, which are intended to better mimic aspects of the human immune system and disease course than standard mouse models.
A defining feature of this opportunity is that awardees are expected not only to pursue their own research aims, but also to contribute to consortium-wide deliverables. The BCBC is charged with collaboratively generating and validating shared research tools such as specialized reagents, mouse strains, antibodies, assays, protocols, and enabling technologies. The emphasis on validation is important: the program is not just about making new tools, but making sure they are robust and broadly useful to the community, helping standardize methods and accelerate progress across multiple projects.
The mechanism is a U01 cooperative agreement, which typically means there is substantial scientific involvement by NIH program staff compared with a standard investigator-initiated grant. Practically, applicants should expect a more structured environment with consortium coordination, shared milestones, and active participation in collaborative planning and resource sharing. The opportunity is categorized as discretionary funding and listed under CFDA 93.847 (Diabetes, Digestive, and Kidney Diseases Extramural Research).
In terms of scope and budget, NIDDK anticipated a total of about $12 million in FY2010 to support this initiative, with an expected 6 to 10 awards. The announcement notes that NIDDK financial plans supported the first two years of the program, while funding for years 3 through 5 would be contingent on the availability of funds. In other words, the program was designed with a multi-year horizon, but later-year support was not guaranteed and depended on appropriations and institute priorities.
Eligibility is broad and includes a wide range of domestic and non-domestic institutions and organization types. Eligible applicants include public and private institutions of higher education, nonprofits (including 501(c)(3) and certain non-501(c)(3) entities), for-profit organizations (including small businesses and other for-profit entities), state governments, and certain Native American tribal governments and tribal organizations. The eligibility list also explicitly includes several categories of institutions aimed at broadening participation, such as Historically Black Colleges and Universities (HBCUs), Hispanic-Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and foreign organizations (non-U.S. entities). There is no cost sharing or matching requirement stated in the opportunity.
Key dates included a posted/creation date of August 14, 2009, with an original and current closing date of November 23, 2009, and an archive date of December 24, 2009. Additional details were made available through the NIH Grants Guide link associated with the RFA, and NIH provided a general point of contact for technical issues accessing the full announcement through the NIH Office of Extramural Research (OER) webmaster.
Frequently Asked Questions (FAQ)
What is the Beta Cell Biology Consortium (BCBC) U01 funding opportunity?
The Beta Cell Biology Consortium (BCBC) U01 funding opportunity (RFA-DK-09-011) is a National Institutes of Health (NIH) program led by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). It is designed to build a coordinated, multi-institution research consortium focused on advancing beta cell biology and translation-relevant strategies for diabetes.
What is the main goal of this consortium?
The goal is to fund several research teams under a cooperative agreement structure so they work in a deliberately collaborative way, share data and materials, and collectively produce validated research resources that would be difficult for any single lab to generate alone.
Which NIH Institute leads this program?
The program is led by NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases), within NIH.
What grant mechanism is being used?
The mechanism is a U01 cooperative agreement. This typically involves substantial scientific involvement by NIH program staff compared with a standard investigator-initiated grant.
How is a U01 cooperative agreement different from a standard NIH research grant?
Based on the opportunity description, applicants should expect a more structured, consortium-based environment with coordination across awardees, shared milestones, and active participation in collaborative planning and resource sharing, along with NIH program staff scientific involvement.
What scientific areas does this funding opportunity support?
The announcement targets four major research directions connected to restoring or preserving functional insulin-producing beta cells:
- Using knowledge and signals from pancreatic development to guide direct differentiation of pancreatic beta cells and islets from stem cells or progenitor cells (with a long-term aim of enabling cell replacement therapies).
- Stimulating beta cell regeneration in the adult pancreas to increase beta cell mass in people with diabetes.
- Cellular reprogramming approaches to convert progenitor or adult cell types into pancreatic beta cells, in vitro or in vivo (also framed as a route toward cell replacement therapies).
- Studying progression of human type 1 diabetes using patient-derived cells and tissues transplanted into humanized mouse models that better mimic aspects of the human immune system and disease course than standard mouse models.
Does the program focus on type 1 diabetes specifically?
One of the four targeted research directions explicitly addresses the progression of human type 1 diabetes using patient-derived cells and tissues transplanted into humanized mouse models.
Does the program include stem cell-related work?
Yes. One targeted direction supports using knowledge and signals from pancreatic development to guide direct differentiation of pancreatic beta cells and islets from stem cells or progenitor cells.
Does the program support beta cell regeneration research?
Yes. A major research direction is stimulating beta cell regeneration in the adult pancreas, emphasizing approaches that could increase beta cell mass in people with diabetes.
Does the program support cellular reprogramming approaches?
Yes. Another targeted direction is cellular reprogramming to convert progenitor or adult cell types into pancreatic beta cells either in vitro or in vivo.
What are “humanized mouse models†in the context of this opportunity?
In this announcement, humanized mouse models are described as models intended to better mimic aspects of the human immune system and the course of human type 1 diabetes than standard mouse models, using patient-derived cells and tissues transplanted into these models.
Are awardees expected to do more than their own project research?
Yes. A defining feature is that awardees are expected to contribute to consortium-wide deliverables in addition to pursuing their own research aims.
What kinds of consortium-wide deliverables are expected?
The BCBC is charged with collaboratively generating and validating shared research tools and resources, including specialized reagents, mouse strains, antibodies, assays, protocols, and enabling technologies.
Why does the announcement emphasize validation of tools and resources?
The emphasis is that the program is not only about creating new tools, but about ensuring they are robust and broadly useful to the community, helping standardize methods and accelerate progress across multiple projects.
Is there an existing consortium network or infrastructure associated with this program?
Yes. The opportunity is associated with the BCBC website (www.betacell.org), indicating an organized network with shared goals and infrastructure.
How much funding did NIDDK anticipate for this initiative?
NIDDK anticipated a total of about $12 million in FY2010 to support the initiative.
How many awards were expected?
The announcement expected approximately 6 to 10 awards.
Was funding for all years guaranteed?
No. The announcement notes that NIDDK financial plans supported the first two years of the program, while funding for years 3 through 5 would be contingent on the availability of funds.
What does “contingent on the availability of funds†mean for years 3 through 5?
It means the program was designed with a multi-year horizon, but later-year support was not guaranteed and would depend on available funding, appropriations, and institute priorities.
What is the CFDA number for this opportunity?
The opportunity is listed under CFDA 93.847 (Diabetes, Digestive, and Kidney Diseases Extramural Research).
Is this a discretionary funding opportunity?
Yes. The opportunity is categorized as discretionary funding.
Who is eligible to apply?
Eligibility is broad and includes many domestic and non-domestic institutions and organization types, including:
- Public and private institutions of higher education
- Nonprofits (including 501(c)(3) and certain non-501(c)(3) entities)
- For-profit organizations (including small businesses and other for-profit entities)
- State governments
- Certain Native American tribal governments and tribal organizations
- Historically Black Colleges and Universities (HBCUs)
- Hispanic-Serving Institutions
- Tribally Controlled Colleges and Universities (TCCUs)
- Alaska Native and Native Hawaiian Serving Institutions
- Foreign organizations (non-U.S. entities)
Are non-U.S. (foreign) organizations eligible?
Yes. The eligibility list explicitly includes foreign organizations (non-U.S. entities).
Is cost sharing or matching required?
No. The opportunity states there is no cost sharing or matching requirement.
What were the key dates for this opportunity?
The posted/creation date was August 14, 2009. The original and current closing date was November 23, 2009. The archive date was December 24, 2009.
Where could applicants find the full announcement details?
Additional details were provided through the NIH Grants Guide link associated with the RFA.
Who was listed as a contact for technical issues accessing the full announcement?
NIH provided a general point of contact for technical issues via the NIH Office of Extramural Research (OER) webmaster.
Browse more opportunities from the same category: Food and Nutrition Health
Next opportunity: NIDCR Dentist Scientist Pathway to Independence Award (K99/R00)
Previous opportunity: Notice of Intent to Award
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DK 09 011
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DK 09 011) also looked into and applied for these:
| Funding Opportunity |
|---|
| Limited Competition for Continuation of the Randomized Intervention for Vesicoureteral Reflux (RIVUR) (U01) Apply for RFA DK 09 502 Funding Number: RFA DK 09 502 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Limited Competition Clinical Centers and Data Coordinating Center for the Complementary and Alternative Medicine for Urological Symptoms (CAMUS) Trial (U01) Apply for RFA DK 09 503 Funding Number: RFA DK 09 503 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Limited Competition Coordinating Center For The Beta Cell Biology Consortium (U01) Apply for RFA DK 09 504 Funding Number: RFA DK 09 504 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Stimulating Hematology Investigation New Endeavors (SHINE) (R01) Apply for PAS 10 046 Funding Number: PAS 10 046 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Human Brown Adipose Tissue Methods for Measurement of Mass and Activity (R21) Apply for RFA DK 10 002 Funding Number: RFA DK 10 002 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $200,000 |
| Planning Centers for Interdisciplinary Research in Benign Urology (IR BU) (P20) Apply for RFA DK 10 001 Funding Number: RFA DK 10 001 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $200,000 |
| Polycystic Kidney Disease (PKD) Research and Translation Core Centers (P30) Apply for RFA DK 09 007 Funding Number: RFA DK 09 007 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $750,000 |
| Limited Competition for the Continuation of the Pediatric Acute Liver Failure Study Group (U01) Apply for RFA DK 09 505 Funding Number: RFA DK 09 505 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $700,000 |
| Limited Competition for the Continuation of the Adult Acute Liver Failure Study Group (U01) Apply for RFA DK 09 506 Funding Number: RFA DK 09 506 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $600,000 |
| NIDDK Central Repositories Non renewable Sample Access (X01) Apply for PAR 10 090 Funding Number: PAR 10 090 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| NIDDK Education Program Grants (R25) Apply for PAR 10 092 Funding Number: PAR 10 092 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| NIDDK Centers of Excellence in Molecular Hematology (P30) Apply for RFA DK 09 013 Funding Number: RFA DK 09 013 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $750,000 |
| Nutrition Obesity Research Centers (P30) Apply for RFA DK 10 003 Funding Number: RFA DK 10 003 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $750,000 |
| Child Survival Health Grants Program Apply for USAID M OAA GH HSR 10 403 Funding Number: USAID M OAA GH HSR 10 403 Agency: Agency for International Development Category: Food and Nutrition Health Funding Amount: $1,750,000 |
| Grants for Research in Glomerular Diseases (R01) Apply for PA 10 113 Funding Number: PA 10 113 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Home and Family Based Approaches for the Prevention or Management of Overweight or Obesity in Early Childhood (R21) Apply for PA 10 128 Funding Number: PA 10 128 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $200,000 |
| Home and Family Based Approaches for the Prevention or Management of Overweight or Obesity in Early Childhood (R01) Apply for PA 10 127 Funding Number: PA 10 127 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Adherence Studies in Adolescents with Chronic Kidney or Urologic Diseases, or Diabetes (R01) Apply for RFA DK 10 004 Funding Number: RFA DK 10 004 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $500,000 |
| Limited Competition for the Continuation of the Consortium for Radiologic Imaging Studies in Polycystic Kidney Disease (CRISP) (U01) Apply for RFA DK 10 501 Funding Number: RFA DK 10 501 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $225,000 |
| Ancillary Studies in Immunomodulation Clinical Trials (R01) Apply for RFA AI 10 014 Funding Number: RFA AI 10 014 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $250,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DK 09 011", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.